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Plasma homovanillic acid (pHVA) levels were estimated in 20 cases of schizophreniform disorder, 14 
cases of schizophrenia 'on medication' and 17 cases of schizophrenia 'off medication'. A bimodal 
distribution ofpHVA was seen in schizophreniform disorder subjects, suggesting heterogenous groups 
in terms of dopaminergic function. No significant difference in the pHVA values was seen in the 3 
groups, nor was there a relationship between the severity of the illness and the pHVA values; these 
results suggest plasticity of the dopaminergic system to neuroleptics. 
M. he dopamine hypothesis of schizophre-
nia is founded on the observation that antipsy-
chotics are potent dopamine (DA) antagonists 
and that clinical potency of these drugs parallels 
their affinity for dopamine receptors. The quan-
tification of the DA metabolite, homovanillic 
acid (HVA), in body fluids is one of the most 
commonly used methods for studying DA trans-
mission in the brain (Degrell and Nagy, 1990)Of 
late, there is a renewed interest in the study of 
DA metabolism using levels of plasma HVA 
(pHVA) as an index of central DA activity 
(Davila, 1989; Chang et al, 1990). 
Various findings have led to the inter-
pretation that about 30-50% of pHVA is of 
central origin (Bacopoulos et al, 1979; Mass et 
al., 1980; Stenberg, 1983). Both animal and 
human 'data suggest that pHVA levels quanti-
tatively reflect brain DA metabolism (Bacopou-
lous et al., 1979, Stenberg et al., 1983, Kendler et 
al., 1982). However, studies of pHVA concen-
trations in schizophrenic patients have pro-
duced inconsistent results (Pickar et al., 1984, 
1986; Davidson et al., 1987; Davidson and 
Davis, 1988; Chang et al., 1988, Davila, 1989, 
Chang etal., 1990). 
The present study addressed the pHVA 
levels in three sub-populations of schizophrenia 
(DSM III): drug-naive schizophreniform disor-
der, schizophrenia on neuroleptic treatment 
and schizophrenia off neuroleptics for more 
than 3 months. The objectives of the study were 
to analyse the distribution of pHVA and the 
relationship of pHVA to degree of psychopa-
thology in these three groups. 
MATERIAL AND METHODS 
X he sample comprised all adult males (20-
40 years of age) diagnosed on DSM III as 
schizophreniform disorder (drug- naive) or 
schizophrenia (on or off medication), present-
ing over a 6 month period at the Department of 
Psychiatry at a general hospital in the city. For 
schizophrenia patients, operationalization of 
'on medication' status was daily neuroleptic use 
for at least the preceding 6 months, while oper-
ationalization of 'off medication' status was 
non- ingestion of oral neuroleptics for at least 
the preceding 3 weeks, or non-use of parenteral 
neuroleptics for at least the preceding 3 months. 
After confirming suitability for entry into 
the study, and after obtaining informed consent, 
the subjects were admitted to the hospital. The 
study was conducted while they remained as 
inpatients. Within 72 hours, the subjects under-
went detailed medical and psychiatric evalua-
tion including a confirmation of the diagnosis. 
They were placed on a low catecholamine diet, 
prepared at the hospital, for 3 days. They were 
kept fasting and at complete bed rest for atleast 
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14 hours immediately prior to collection of a 
blood sample. 5 ml of venous blood was col-
lected in a heparinised tube at 9 a.m. Within 10 
minutes, the plasma was separated by centrifu-
gation and stored at -70 C until assay. 
The plasma homovanillic acid concen-
tration was determined by the extraction proce-
dure described by Chang et al. (1983) followed 
by high pressure liquid chromatography 
(HPLC) with electrochemical detection 
(Pradhanefaf.,1990). 
The subjects were rated on the Brief 
Psychiatric Rating Scale (BPRS; Overall and 
Gorham, 1962). The rating was subscaled into 
schizophrenic thought disorder symptoms 
(subscale-1), schizophrenic non-thought disor-
der symptoms (subscale-2) and non-schizo-
phrenic symptoms or arousal symptoms 
(subscale-3) as described by Yorkston et al. 
(1974). The raters were blind to the diagnostic 
status of the subjects. The rating was done at a 
fixed time -10.30 a.m. on the day prior to blood 
sampling. 
During the study, the 'on medication' 
schizophrenic group continued their drugs in 
the dose prescribed to them by the treating 
psychiatrist. The drug-naive schizophreniform 
disorder and the 'off medication' schizophrenic 
patients did not receive any neuroleptics other 
than diazepam in an oral dose of lOmg S.O.S. 
RESULTS 
J. he original sample comprised 60 sub-
jects; 3 of these were dropped because of haer 
molysis of their blood samples and 4 more were 
dropped because of failure to comply with the 
requirements of the study protocol. Of the re-
maining 53, 2 subjects, one from group A and 
one from group C, were excluded from the 
analysis because of outlying pHVA values (the 
values were 4-5 times greater than the mean of 
their respective groups). Thus, the final sample 
comprised 20 in group A (drug-naive 
schizophreniform disorder), 14 in group B 
(schizophrenia 'on medication') and 17 in group 
C (schizophrenia 'off medication'). 
The mean (M),±standard deviation 
(SD) age in Groups A, B and C were 26.5 ±5.9, 
31.0±6.5 and 33.0±5.9 respectively; Group A 
was significantly younger (p <0.05) than 
Groups B and C (one way ANOVA with Stu-
dent-Newman-Keuls multiple comparison 
test). The BPRS full scale and subscale scores 
were presented in Table-1. The group A sub-
jects were significantly more ill than the group 
B or group C subjects on the total BPRS scale 
and on subscales 1 and 2, but there was no 
significant difference between groups B and C 
(one way ANOVA with Student-Newman-
Keuls' multiple comparison test). 
D'Agostino's test of normality, a power-
ful test to detect non-normal distributions (Zar, 
1984), was applied to the pHVA values in each 
of the 3 groups. Non-normal distribution was 
identified in Group A (D = 0.2516, p) but not in 
groups B (D= 0.275, p>0.2) and C 
(D = 0.2751, p> 0.2). 
There was no correlation between 
pHVA values and BPRS full scale or subscale 
scores in the 3 groups (Table-2). To test the 
association of higher pHVA values (in the ab-
sence of one to one correspondence) with 
greater degree of psychopathology, the pHVA 
values were divided by a median split; the M 
±SD full scale and subscale BPRS scores in 
'high HVA' and 'low HVA' categories in the 3 
groups were compared. No significant associa-
tion emerged (Table-3). 
The pHVA values were compared in 
groups A (57.8±34.9), B (67.8±41.9) and C 
(55.1±32.9); there was nosignificant difference 
(one way ANOVA). 130  N.PRADHAN etal. 
DISCUSSION 
J. wo of the subjects who completed the 
study protocol had to be dropped from analysis 
because of outlying pHVa values. It is difficult 
to speculate on the reasons responsible for lev-
els so far removed from the rest of the group, 
but such outlying values are not uncommon in 
biological ressearch. These values if retained in 
the analysis, could potentially cause a skewed 
distribution and prejudice the statistical infer-
ences. 
Although the 3 groups differed in age, 
this was not considered as a separate indepen-
dent variable as there is no evidence that pH VA 
varies with age in young adults, especially within 
a narrow span (difference between extreme 
means = 6.5 years). 
The schizophreniform disorder subjects 
were more severely ill than the schizophrenics 
(Table-1). This could be expected, as these sub-
jects were preselected for being drug-naive, and 
were actively psychotic, while the schizophre-
nics 'on medication, were largely in remission, 
and the schizophrenics 'off medication' were 
mostly asymptomatic (having the lowest scores 
on BPRS). However, the scores did not differ 
significantly between groups B and C. 
Table-1: Mean ± Standard Deviation Brief Psychiatric Rating Scale (BPRS) and subscale 
scores in groups A, B and C 
BPRS Scores 
BPRS Total 
Subscale 1 
Subscale 2 
Subscale 3 
Group A 
(n-20) 
49.8±8.7 
15.0±3.4 
18.8±5.1 
16.0±3.9 
Group B 
(n-14) 
36.8±14.1 
7.0±5.2 
13.4±3.8 
16.4±7.2 
Group C 
(n = 17) 
28.0±11.3 
4.5±3.6 
10.9±4.7 
12.5±4.3 
Significance 
F (2,48) = 17.62, p < 0.001, AB; AC 
F (2,48) = 33.91, p < 0.001, AB; AC 
F (2,48) = 14.16, p < 0.001, AB;AC 
N.S. 
*One wayANOVA with Student-Newman-Keuls'multiple comparison test 
A non-normal distribution of pH VA was 
observed in group A. An examination of the raw 
data revealed 2 clusters, one between 20-60 
ng/ml, and other between 100-140 ng/ml. The 
difference in the severity of the illness did not 
account for this bimodal distribution ( Table-2 
and 3). It is speculated that at least two 
dopaminergic subtypes of schizophreniform 
disorders may exist, one with high and the other 
with low dopaminergic activity. Interestingly, a 
similar hypothesis has been proposed by Chang 
et al. (1990) in their studies with DSM III diag-
nosed schizophrenia, based on the baseline 
pHVA, response to haloperidol challenge and 
treatment response. However, in this study 
there was no non-normal distribution or dichot 
Table-2: Pearson's product-moment correla-
tion coefficients (r) for pHVA Values and cor-
responding BPRS Scores In group A, group 
B and group C. 
BPRS 
BPRS Total 
Subscale 1 
Subscale 2 
Subscale 3 
Group A 
(n=20) 
0.18 
0.21 
0.00 
0.21 
Group B 
(n = 14) 
-0.32 
-0.34 
-0.14 
-0.30 
Group C 
(n = 17) 
-0.17 
-0.22 
0.17 
-0.08 
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omy in the baseline values in schizophrenia' on 
medication' or in schizophrenia 'off medication' 
groups. This study hence suggests that the DSM 
III diagnosis of schizophreniform disorder may 
represent a heterogenous group biochemically, 
while DSM III schizophrenia may truly repre-
sent a biologically homogenous group in terms 
of central dopaminergic acivity. 
The absence of significant correlations 
between pHVA values and BPRS scores 
(Table-2) indicates an absence of a one to one 
relationship between pHVA and symptomatol-
ogy. Since these results do not preclude the 
possibility of association of high pHVA with 
more severe symptoms, further analysis was 
conducted (Table-3.) but again with negative 
results. These findings are not in consonance 
with the dopaminergic hypothesis of schizo-
phrenia, and are in sharp contrast to certain 
other studies ( Davis et al., 1985; Davidson and 
Davis, 1988; Mass et al., 1988). It has been re-
marked that controversies and contradictions 
are two common features of pHVA studies due 
to variations in the study designs (Davila, 1989). 
In this study, the role of dopaminergic activity 
in severity of schizophrenic symptomatology 
could not be established. The same conclusion 
has been derived from the inter-group compar-
ison of pHVA values (Table-1). Despite differ-
ing degrees of psychopathology, pHVA levels 
did not differ significantly between the 3 groups. 
Table-3 : Mean ± Sd BPRS Scores in higher and lower pHVA categories In group A, group B 
and group C. 
BPRS Scores 
BPRS Total 
Subscale 1 
Subscale 2 
Subscale 3 
Group 
Median 
(n = 10) 
50.74.1 
15.13.5 
18.93.5 
16.7 3.5 
»A 
Median 
(n = 10) 
48.9 12.0 
14.93.6 
18.76.4 
15.34.3 
Group 
Median 
(n=7) 
50.74.1 
15.13.5 
18.93.5 
16.7 3.5 
»B 
Median 
(n=7) 
48.912.0 
14.93.6 
18.76.4 
15.34.3 
Group C 
Median 
(n = 8) 
50.7 4.1 
15.13.5 
18.93.5 
16.73.5 
Median 
(n=9) 
48.912.0 
14.93.6 
18.76.4 
15.34.3 
All t test comparisons (with modified degrees of freedom wherever indicated, to correct for heteroge-
neity of variances), between above median and below median categories within each of the three 
groups, were non-significant. 
The pHVA values in group B were not 
significantly different from those in groups A 
and C. The expected rise of pHVA values with 
neuroleptic therapy (indicating increased do-
pamine turnover in a homeostatic effort to over-
come to dopaminergic blockade) was not seen 
in this group. The finding, however, could be 
understood in the light of development of either 
tolerance in dopaminergic neurons to chronic 
D2 receptor blockade or supersensitivity of D2 
autoreceptors (Davila, 1989, Langer and Leh-
mann, 1988). 
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